Dynocardia in the News!

June, 2026

SBIR Innovation Index Spotlight: Dynocardia

Dynocardia's HHS SBIR Phase II award to complete design verification and validation of ViTrack highlighted in the Innovation Index.

In U.S. hospitals, 35 million critically ill patients annually require blood pressure monitoring. Current non-invasive technologies are occlusive arm cuff-based and provide only single-point measurements, leading to monitoring gaps and 14 million episodes of acute kidney injury and myocardial injury annually. Dynocardia's ViTrack — a cuff-less, wrist-wearable device with a proprietary optomechanical sensor and computer vision technology — may be the first to measure beat-to-beat systolic and diastolic blood pressures directly without external calibration, irrespective of subject movement or wrist position. In prior clinical testing against intra-arterial pressure in 60 patients, ViTrack demonstrated accurate, continuous readings every 20 seconds regardless of movement, divergent blood pressures, abnormal heart rhythms, and hemodynamic conditions. This Phase II award supports completion of verification and validation of the production-grade ViTrack hospital device to enable FDA 510(k) clearance submission.

November, 2025

3DEXPERIENCE Lab Alumni: Dynocardia Graduates

Dassault Systemes highlights Dynocardia as one of three healthcare startups that graduated from the 3DEXPERIENCE Lab acceleration program.

Dynocardia, Damae Medical and LUCID Implants - three healthcare startups who have graduated from the 3DEXPERIENCE Lab acceleration program, demonstrating their commitment to changing the world of healthcare through innovation.

October, 2025

ViTrack Results Presented at ANESTHESIOLOGY 2025

Multi-center clinical study results evaluating ViTrack technology presented by Dr. Alparslan Turan.

Against the latest FDA-recommended ISO standard, ViTrack technology consistently delivered accurate, stable BP measurements every 20 seconds and reliably detected significant BP changes when compared to invasive arterial lines, even under real-world conditions such as patient movement and changes in posture.

October, 2025

3DEXPERIENCE Lab: International Day of Elder Persons

Dynocardia featured as a pioneering startup enhancing the lives of elder adults.

At the 3DEXPERIENCE Lab, innovation transforms aging into a journey of dignity, autonomy, and well-being. Dynocardia was featured alongside NeuroServo, Gyrolift, BIOMOTUM, and FEops as pioneering startups developing solutions that directly enhance the lives of elder adults.

May, 2025

MIT Startup Exchange Spotlight: Dynocardia

Dynocardia featured for its innovative wearable device for continuous blood pressure monitoring.

Dynocardia, a digital healthcare company, is introducing an innovative wearable device designed for the continuous monitoring of blood pressure and heart function throughout the entire healthcare continuum. By utilizing real-world data and advanced AI, it aims to proactively predict adverse events, prevent heart disease, and slow down vascular aging.

April, 2025

Ranked #8 U.S. Biomedical Engineering Company

From the F6S Community: Dynocardia ranked among top U.S. biomedical engineering companies.

Dynocardia ranked 8th among top U.S. biomedical engineering companies and startups for its fundamentally different approach to continuously measuring blood pressure non-invasively.

December, 2024

Dynocardia Secures $1M NSF Grant to Advance ViTrack Technology

Revolutionizing Continuous Blood Pressure Monitoring with Motion-Correction Technology

Cambridge, MA. – December 3, 2024. Dynocardia has been awarded a $1 million grant by the National Science Foundation (NSF) to enhance its innovative computer vision-based motion-artifact mitigation technology.

Read the full press release
October, 2024

Press Release:

Dynocardia's Direct Continuous Blood Pressure Monitoring Technology Receives Grant from NIH's Commercialization Readiness Pilot Program

CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- The National Heart, Lung, and Blood Institute (NHLBI) has awarded Dynocardia a $500,000 grant under its Commercial Readiness Pilot (CRP) Program.

Read the full press release
September, 2024

2024 Engineering for Women's Health Conference

Jordan Parker-Ashe and Victoria Gonzalez-Canalle represented Dynocardia at the 2024 Engineering for Women's Health conference hosted by Northeastern University.

Our biomedical engineers represented Dynocardia at the 2024 Engineering for Women's Health conference. This experience was especially meaningful, as Dynocardia is conducting ongoing clinical trials involved in maternal health.

Image
August, 2024

NIH Funding Insights with Dynocardia at #HRX2024

NIH Funding Opportunities

Dynocardia had the chance to explore NIH funding opportunities at #HRX2024 with Julia Berzhanskaya from NHLBI and a distinguished panel including Renée Arnold, Ken Nelson, and Mohan Thanikachalam.

Image
July, 2024

Dynocardia Advances Cuff-Less Blood Pressure Tech with PracticePoint

Dynocardia's innovative cuff-less monitor gets a boost from PracticePoint's advanced tech and expertise.

Dynocardia, Inc. has achieved a significant breakthrough in wearable health technology with PracticePoint's advanced support and expertise.

Image
June, 2024

Leading Player in the Blood Pressure Monitoring Market

Dynocardia Stands Out Among Top Blood Pressure Monitoring Innovators

Dynocardia is recognized as a leading player in the blood pressure monitoring market during the forecast period from 2024–2030.

June, 2024

MIT Startup Exchange

Dynocardia highlights Advances in Digital Health at 2024 MIT Webinar

Dynocardia, Inc. was delighted to join the 2024 MIT Digital Health and Wellness webinar. Prof. Mohan Thanikachalam highlighted our latest innovations in personalized patient care using real-time data.

Image
June, 2024

Dynocardia Shines at Boston Startup Events

Dynocardia Presents at Boston's Esteemed Startup Events

Dynocardia joined Jose Tomas Dominguez Fuenzalida of Atcama Biomaterials at Greentown Labs. Our collaboration with the 3DEXPERIENCE Lab has been fantastic.

Image
June, 2024

Dynocardia's CPO, José Wong Joins PracticePoint Advisory Board

José Wong, our Chief Product Officer, has joined the PracticePoint Advisory Board at Worcester Polytechnic Institute.

Image
May, 2024

Dynocardia at DeviceTalks Boston

Dynocardia's Innovations Highlighted in DeviceTalks Boston Panel on In Silico Clinical Trials

We have been a part of an electric panel discussion with Steve Levine, David Hoganson, Ellen Roche, and Mohan Thanikachalam focusing on the entire life cycle of In Silico Clinical Trials.

Image
March, 2024

Mohan Thanikachalam Elevated to Senior Member at National Academy of Inventors

Tufts Faculty Member, Mohan Thanikachalam Honored as Senior Member of the National Academy of Inventors

Mohan Thanikachalam, Research Assistant Professor of Public Health & Community Medicine at Tufts University, has been recognized as a senior member of the National Academy of Inventors.

Image
March, 2024

ViTrack's Impact on Maternal and Child Health During Pregnancy

NIH Awards $2.3M to Study ViTrack's Impact on Maternal and Child Health During Pregnancy

ViTrack stands out as a solution capable of providing continuous, accurate blood pressure measurements regardless of patient movement or wrist position using computer vision and artificial intelligence.

Image
November, 2023

Dynocardia at MIT Madrid Symposium

Revolutionizing Healthcare Through Cutting-Edge Research and Technology

Dynocardia participated in the prestigious MIT Madrid Symposium, where our cutting-edge research and innovative technology took center stage.

MIT ILP Image
November, 2023

Dassault System's 3D Experience Lab Accelerator

Dynocardia working with Dassault System's 3D Experience Lab Accelerator

Dynocardia is happy to partner with Dassault Systèmes' 3D Experience Lab Accelerator, a renowned platform for innovation and breakthrough technologies.

November, 2023

HRX 2023 Breakthrough Innovation Award

Dynocardia wins Breakthrough Innovation Award in Cardiovascular health at HRX 2023

We're honored to have won first place in the #HRX2023 Breakthrough Innovation Award in Cardiovascular Digital Health for ViTrack™.

Image
0
Skip to Content
Dynocardia
ABOUT
APPLICATIONS
TECHNOLOGY
TEAM
CLINICAL PROGRAM
NEWS
CONTACT
Dynocardia
ABOUT
APPLICATIONS
TECHNOLOGY
TEAM
CLINICAL PROGRAM
NEWS
CONTACT
ABOUT
APPLICATIONS
TECHNOLOGY
TEAM
CLINICAL PROGRAM
NEWS
CONTACT

Wendy Wilcox, MD, Chief Women’s Health Officer, NYC Health + Hospitals

“Hypertensive disorders of pregnancy pose a growing threat to pregnant women, especially among Black patients and other patients of color who bear a disproportionate burden of maternal mortality and severe maternal morbidity. After an extensive review, the NHLBI selected ViTrack to address this challenge. We’re excited about the potential to mitigate risk among the women who rely on us for their prenatal care”